Form 8-K - Current report:
SEC Accession No. 0001558370-25-007253
Filing Date
2025-05-12
Accepted
2025-05-12 07:37:22
Documents
16
Period of Report
2025-05-12
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K pmn-20250512x8k.htm   iXBRL 8-K 37671
2 EX-99.1 pmn-20250512xex99d1.htm EX-99.1 147993
3 GRAPHIC pmn-20250512xex99d1001.jpg GRAPHIC 6463
  Complete submission text file 0001558370-25-007253.txt   342167

Data Files

Seq Description Document Type Size
4 EX-101.SCH pmn-20250512.xsd EX-101.SCH 4050
5 EX-101.DEF pmn-20250512_def.xml EX-101.DEF 2874
6 EX-101.LAB pmn-20250512_lab.xml EX-101.LAB 17909
7 EX-101.PRE pmn-20250512_pre.xml EX-101.PRE 11840
18 EXTRACTED XBRL INSTANCE DOCUMENT pmn-20250512x8k_htm.xml XML 5044
Mailing Address SUITE 200, 1920 YONGE STREET TORONTO A6 M4S 3E2
Business Address SUITE 200, 1920 YONGE STREET TORONTO A6 M4S 3E2 416-847-6898
ProMIS Neurosciences Inc. (Filer) CIK: 0001374339 (see all company filings)

EIN.: 000000000 | State of Incorp.: Z4 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-41429 | Film No.: 25932601
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)